Novo Nordisk Soars 19% in a Month: How Should You Play the Stock?

Key Takeaways NVO recently gained FDA approval and launched oral Wegovy, the first GLP-1 RA pill for weight management.NVO beat Eli Lilly to market with an oral obesity drug, gaining an edge as GLP-1 competition intensifies.Novo Nordisk filed for CagriSema, a next-gen combo injection for obesity, with FDA review expected in 2026.Novo Nordisk (NVO) shares have surged 18.8% in the past month. The stock price gain was primarily induced by the much-anticipated FDA approval of NVO’s Wegovy pill (once-daily oral ...